55th Annual Meeting (October 28-November 2, 2008): Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder in Children and Adolescents (6 – 17 years old): Results from a Fixed Dose, Double-Blind, Randomized, Placebo-Controlled Trial

Thursday, October 30, 2008: 11:30 AM

River Exhibition Hall (Sheraton Chicago Hotel & Towers)

Randall Owen, M.D.,

Ronald Marcus, M.D.,

Michael G. Aman, Ph.D., Ohio State University, Columbus, OH

George Manos, Ph.D., Bristol-Myers Squibb, Wallingford, CT

Raymond Mankoski, M.D., Ph.D., Bristol-Myers Squibb, Plainsboro, NJ

Sheila Assuncao-Talbott, M.D., Ph.D.,

Margaretta Nyilas, M.D., Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ

Taro Iwamoto, Ph.D., Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ

William Carson, M.D., Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ

Dan A. Oren, M.D., Bristol-Myers Squibb, Woodbridge, CT

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 3.59 Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder in Children and Adolescents (6 – 17 years old): Results from a Fixed Dose, Double-Blind, Randomized, Placebo-Controlled Trial